Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2012

View Archived Issues

Sanofi reviews progress of 2011

New serotonin receptor antagonist shows promise to treat cognitive deficiencies

German study reveals new prognostic marker for penile cancer

Boehringer Ingelheim presents new therapeutic candidates for hepatitis C

New B-raf inhibitors developed by Nerviano Medical Sciences

AstraZeneca reports novel potential cancer therapies

New candidate schizophrenia therapeutics developed in Japan

Merck & Co. research yields novel anti-infectives

New multifuctional pactamycin analogues synthesized in U.S.

Novavax kicks off phase II trial of quadrivalent flu vaccine

Tekmira Pharmaceuticals adds new RNAi therapeutic to pipeline

Proximagen VAP-1 inhibitor enters phase I study

Galapagos receives milestones payments in osteoarthritis alliance

Urinary biomarker may be useful to detect and monitor kidney damage

Ablynx provides pipeline update

Arena Pharmaceuticals files MAA for weight control drug

Phosphagenics and Nippon Zoki sign prelicensing agreement

Second milestone reached in Ipsen/Photocure collaboration

SK Biopharmaceuticals obtains funding for lead program in refractory epilepsy

FDA approves two Aptalis Pharma pancrelipase products

First-in-human study of implantable drug delivery microchip succeeds

New PEGylated G-CSF conjugates developed to treat neutropenia

Merck & Co. describes novel vaccines

New study investigates cabozantinib combined with abiraterone

Aegerion files applications for cholesterol-lowering agent in U.S. and E.U.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...